A game-changer in dermatology

17MarMarch 17, 2025

[videojs_video url=’https://du7x25at22z7c.cloudfront.net/IV_BOT_250310_HowieMcKibbon/single_720p.mp4′ poster=’http://www.finnewsnetwork.com.au/newssystem/seqcmsfiles/2025/03/DvozQAF5idb8Nvm0z38e_1920x1080_13406.jpg’]

Dr Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT), discusses the FDA approval and market success of Sofdra, the first new chemical entity approved for primary axillary hyperhidrosis. Launched in the US in February 2024, the treatment has seen strong prescription growth, supported by extensive insurance coverage and a high-performing sales team. The company’s strategy focuses on patient adherence, facilitated by automatic prescription refills and co-pay assistance. A newly launched digital marketing initiative aims to reach millions searching for online treatment options.

Source: Finance News Network

19JunJune 19, 2024

Investing in childcare

19 Jun 2024 - Patrick Bell, CEO and Director of Finexia Financial Group (ASX:FNX) speaks to Garry Crole, CEO and Managing Director of Sequoia Financial Group (ASX:SEQ). Topics discussed include the company's Childcare Income Fund and its lending business.

17DecDecember 17, 2019

Wisr (ASX:WZR) partners with NAB

17 Dec 2019 - Wisr Limited (ASX:WZR) CEO, Anthony Nantes talks about the company's partnership with NAB to provide an initial $50m in funding to support its personal loan book and diversify its funding partners.

17MayMay 17, 2023

Fifty times more valuable than LNG: Searching for helium in Tanzania

17 May 2023 - Noble Helium Limited (ASX:NHE) Co-Founder and CEO Justyn Wood discusses the demand for and pricing of helium, the geology of the company's project in Tanzania, plans for helium transport and outlook.

13SepSeptember 13, 2022

Imdex (ASX:IMD) announces commercial contract for Blast Dog technology

13 Sep 2022 - Imdex Limited (ASX:IMD) CEO Paul House discusses FY22 financial and operational highlights, the first commercial contract for Blast Dog, growth opportunities and outlook.

16OctOctober 16, 2023

Golden Mile Resources discusses vermiculite-hosted nickel

16 Oct 2023 - Damon Dorman, the Managing Director at Golden Mile Resources (ASX:G88), discusses the discovery of vermiculite in their Quicksilver Nickel project in Western Australia.

20SepSeptember 20, 2022

Radiopharm Theranostics (ASX:RAD) receives FDA designations for DUNP19

20 Sep 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the FDA's award of orphan status and rare paediatric disease designation for the company's DUNP19 technology.

23SepSeptember 23, 2021

AD1 Holdings (ASX:AD1) FY21 results and outlook

23 Sep 2021 - AD1 Holdings Limited (ASX:AD1) CEO and Managing Director Brendan Kavenagh provides an update on the company's suite of software as a service businesses, FY21 results and outlook.

09FebFebruary 9, 2023

What’s the outlook for the listed property sector?

09 Feb 2023 - Sequoia Asset Management Investment Manager Winston Sammut discusses property investment strategy, the impacts of COVID and work from home, shopping malls, industrial property, and alternative property classes.

11MarMarch 11, 2021

Rural Funds Group (ASX:RFF) HY21 results summary

11 Mar 2021 - Rural Funds Group Limited (ASX:RFF) General Manager - Investor Relations and Marketing, James Powell, presents on the group's HY21 results.

26AugAugust 26, 2021

Chimeric Therapeutics (ASX:CHM) – bringing cell therapy to more patients with cancer, August 2021

26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.

A game-changer in dermatology